Dutch Startup QT Sense Gains €6 Million for Quantum Medtech Advancement
Amsterdam, Tuesday, 25 February 2025.
QT Sense secures €6 million to enhance disease diagnostics using nanodiamonds, focusing on early sepsis detection and personalized cancer treatment with high precision quantum sensing.
Quantum Sensing Revolution
QT Sense, founded in February 2024 as a spinout from University Medical Center Groningen, is pioneering quantum sensing technology that could revolutionize medical diagnostics [1]. The startup’s groundbreaking approach uses nanodiamonds to monitor cellular activity at unprecedented precision levels, offering real-time measurements at single-cell resolution [1]. This positions the company at the intersection of quantum technology and medical diagnostics, representing a significant advancement in the quantum sensing field [GPT].
Technology and Leadership
The company’s innovative platform, Quantum Nuova, leverages the unique properties of nanodiamonds to observe cellular behavior with exceptional detail [1]. The technology was developed under the leadership of Prof. Dr. Romana Schirhagl, an expert in quantum sensing, alongside co-founders Dr. Deepak Veeregowda and Hoang Nguyen [1]. Their combined expertise in quantum sensing, life sciences, and business operations has created a unique value proposition in the medical diagnostics sector [1].
Clinical Applications and Future Impact
QT Sense’s technology stands out for its potential to transform multiple areas of healthcare. The platform’s immediate focus includes early sepsis detection and personalized cancer treatment, with the technology being implemented at the Emergency and Acute Care Center at the University Medical Center Groningen [1]. According to Dr. Deepak H. Veeregowda, CEO of QT Sense, their single-cell-level detection capabilities offer ‘much higher precision in diagnosing and understanding diseases,’ surpassing the limitations of current technologies [1].
Investment and Market Position
The €6 million funding round, led by QDNL Participations, represents a strong vote of confidence in QT Sense’s technology [1]. Ton van ‘t Noordende, general partner at QDNL Participations, highlighted the team’s rare combination of quantum sensing and life sciences expertise as a key factor in their investment decision [1]. The funding will support the further development of the Quantum Nuova platform, particularly in its application for cutting-edge sepsis diagnostics research [1]. While the technology shows immense promise, its widespread adoption will depend on proving scalability and cost-effectiveness in clinical settings [1].